CHICAGO — Tests searching for tumor DNA that’s circulating in the blood are surging in popularity, providing clinicians with valuable insights into a patient’s cancer progression well before changes are detectable on traditional imaging scans like MRI or CT. These circulating tumor DNA (ctDNA) tests have the potential to predict cancer recurrence months before visible lesions appear and offer information on how a cancer is responding to specific treatments.
The demand for these tests has skyrocketed, with numerous studies presented at the American Society for Clinical Oncology annual meeting highlighting the utility of ctDNA in guiding clinical decisions. However, despite the excitement surrounding the potential of ctDNA tests, experts caution that more research is needed to determine their effectiveness in improving patient outcomes.
While trials are generating data on ctDNA, the conclusive evidence on whether these tests significantly impact patient care remains elusive. The results are promising, but researchers emphasize the need for more robust studies to validate the clinical utility of ctDNA testing.
To read the rest of this exclusive article and access daily coverage and analysis of the biotech sector, subscribe to STAT+.
Subscribe now to unlock premium content and stay informed on the latest developments in the field of cancer research and treatment.
